KIDNEY INJURY MOLECULE-1 AS AN EARLY AMIKACIN-INDUCED NEPHROTOXICITY MARKER IN PATIENTS WITH SEPSIS HOSPITALIZED IN THE INTENSIVE CARE UNIT
Objective: This study sought to determine the correlation between trough plasma amikacin concentrations and urinary normalized kidney injury
molecule-1 (KIM-1) concentrations as an early biomarker of nephrotoxicity in patients with sepsis who are hospitalized in an intensive care unit.
Methods: In this pilot study, 12 patients with sepsis were treated with amikacin 1000 mg/day between May 2015 and September 2015. The correlation
between trough plasma amikacin concentrations measured after the third dose and the elevation of urinary normalized KIM-1 concentrations after
the third amikacin dose relative to the first/second dose was evaluated.
Results: In total, three patients had trough plasma amikacin concentrations exceeding the safe level (>10 μg/ml). Furthermore, eight patients
displayed higher normalized KIM-1 concentrations after third dose than after the first/second dose; however, there was no correlation between
trough amikacin concentrations and the elevation of urinary normalized KIM-1 concentrations (r=0.3, p=0.3).
Conclusion: The study results illustrated that short-term treatment with an amikacin dose of 1000 mg/day was generally safe in patients with sepsis.
Mojtaheddzadeh M. Influence of sepsis on higher daily dose of amikacin
pharmacokinetics in critically ill patients. Eur Rev Med Pharmacol Sci 2013;
2. Martínez-Salgado C, López-Hernández FJ, López-Novoa JM.
Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl
3. Setiabudy R, Suwento R, Rundjan L, Yasin FH, Louisa M,
Dwijayanti A, et al. Lack of a relationship between the serum
concentration of aminoglycosides and ototoxicity in neonates. Int J Clin
Pharmacol Ther 2013;51:401-6.
4. Deck DH, Winston LG. Aminoglycosides and spectinomycin. In:
Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical
Pharmacology. 12th ed. Singapore: McGraw-Hill; 2012. p. 821-7.
5. Bonventre JV. Kidney injury molecule-1 (KIM-1): Aurinary biomarker
and much more. Nephrol Dial Transplant 2009;24:3265-8.
6. Chaturvedi S, Farmer T, Kapke GF. Assay validation for KIM-1: Human
urinary renal dysfunction biomarker. Int J Biol Sci 2009;5:128?34.
7. Taccone FS, Laterre P, Herbert SH, Dugernier T, Delattre I, Layeux B,
et al. Revisiting the loading dose of amikacin for patients with severe
sepsis and septic shock. Crit Care 2010;14:R53.
8. Petri WA. Aminoglycosides. In: Hardman JG, Limbird LE, editors.
Goodman and Gilman’s the Pharmacological Basis of Therapeutics.
12th ed. New York: McGraw-Hill; 2011. p. 1516-7.
9. Beaucaire G. Does once-daily dosing prevent nephrotoxicity in all
aminoglycosides equally? Clin Microbiol Infect 2000;6:357-62.
10. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult
patients: Insights from the society of infectious diseases pharmacists.
11. Balqis LF, Noormartany, Gondodiputro RS, Rita C. Validity of kidney
injury molecule-1 urin metode mikro enzyme-linked
immunosorbent assay as a early prevention for acute kidney disorders in
sepsis. Majalah Kedokt Bandung 2016;48:19-25.
12. Oliveira JF, Silva CA, Barbieri CD, Oliveira GM, Zanetta DM,
Burdmann EA. Prevalence and risk factor for aminoglycoside
nephrotoxicity in intensive care units. Antimicrob Agents Chemother 2009;
13. Boghdady IM, Naggara MM, Emaraa MM, El-Shazlyb RM,
Mahmouda KS. Kidney injury molecule-1 as an early marker for acute
kidney injury in critically ill patients. Menoufia Med J 2013;26:98-104.
14. Dahlan MS. Using the sample size formula correctly. In: Large Edition
Sample and Sampling Method in Medical and Health Research. Jakarta:
Salemba Medika; 2010. p. 76-7.
This work is licensed under a Creative Commons Attribution 4.0 International License.